Br-101801-Ct-101- A Phase I, Open-Label, Multi-Center, Dose Escalation, And Expansion Study Of Br101801 In Adult Patients With Advanced Hematologic Malignancies
Posted Date: May 7, 2021
- Investigator: Emily Curran
- Specialties: Cancer, Leukemia, Oncology
- Type of Study: Drug
The main purpose of phase 1a of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose for expansion (RDE) of BR101801 in patients with relapsed/refractory advanced hematologic malignancies except acute leukemia and multiple myeloma. The main purpose of phase 1b is to assess tumor response and safety in specific advanced relapsed/refractory hematologic malignances at a dose of BR101801 identified in Phase Ia.
Criteria:
Phase Ia:Patients With Relapsed And/Or Refractory Relapsed/Refractory B-Cell Lymphoma, Cll/Sll, And Ptcl, Ecog 0-2, Life Expectancy More Than 3 Months, No Concurrent Malignant Disease, No Past Or Active Medical Condition Or Infection That May Impact Patie
Keywords:
Leukemia, Multiple Myeloma
For More Information:
Uc Cancer Center
513-584-7658
cancer@uchealth.com